BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32833716)

  • 1. Heparin Anti-Xa Activity, a Readily Available Unique Test to Quantify Apixaban, Rivaroxaban, Fondaparinux, and Danaparoid Levels.
    Boissier E; Senage T; Babuty A; Gouin-Thibault I; Rozec B; Roussel JC; Sigaud M; Ternisien C; Trossaert M; Fouassier M; Lakhal K
    Anesth Analg; 2021 Mar; 132(3):707-716. PubMed ID: 32833716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Xa Oral Anticoagulant Plasma Concentration Assay in Real Life: Rivaroxaban and Apixaban Quantification in Emergency With LMWH Calibrator.
    Billoir P; Barbay V; Joly LM; Fresel M; Chrétien MH; Le Cam Duchez V
    Ann Pharmacother; 2019 Apr; 53(4):341-347. PubMed ID: 30378443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality performance for indirect Xa inhibitor monitoring in patients using international external quality data.
    Hollestelle MJ; van der Meer FJM; Meijer P
    Clin Chem Lab Med; 2020 Oct; 58(11):1921-1930. PubMed ID: 32441664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?
    Shin H; Koh EH; Lee GW; Song HN; Kim HY; Park S
    J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):741-747. PubMed ID: 32113855
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single test to assay warfarin, dabigatran, rivaroxaban, apixaban, unfractionated heparin, and enoxaparin in plasma.
    Letertre LR; Gudmundsdottir BR; Francis CW; Gosselin RC; Skeppholm M; Malmstrom RE; Moll S; Hawes E; Francart S; Onundarson PT
    J Thromb Haemost; 2016 May; 14(5):1043-53. PubMed ID: 26924677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'.
    Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I
    Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation.
    Willekens G; Studt JD; Mendez A; Alberio L; Fontana P; Wuillemin WA; Schmidt A; Graf L; Gerber B; Bovet C; Sauter TC; Nagler M
    Br J Haematol; 2021 Jun; 193(6):1203-1212. PubMed ID: 33954979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective cohort study on the use of low molecular weight heparin calibrated anti-Xa assay for measurement of direct oral Xa inhibitors in ex vivo patient samples.
    Lim MS; Hayes R; Sharma A; Kitiponchai T; Mohamed M; Mcrae S
    Pathology; 2022 Aug; 54(5):599-605. PubMed ID: 35414442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study.
    Gouin-Thibault I; Flaujac C; Delavenne X; Quenet S; Horellou MH; Laporte S; Siguret V; Lecompte T
    Thromb Haemost; 2014 Feb; 111(2):240-8. PubMed ID: 24172843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Anti-Xa Activity in Patients Receiving Apixaban or Rivaroxaban.
    Bookstaver DA; Sparks K; Pybus BS; Davis DK; Marcsisin SR; Sousa JC
    Ann Pharmacother; 2018 Mar; 52(3):251-256. PubMed ID: 29047306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chromogenic anti-FXa assay calibrated with low molecular weight heparin in patients treated with rivaroxaban and apixaban: possibilities and limitations.
    Margetić S; Ćelap I; Delić Brkljačić D; Pavlović N; Šupraha Goreta S; Kobasić I; Lovrenčić-Huzjan A; Bašić Kes V
    Biochem Med (Zagreb); 2020 Feb; 30(1):010702. PubMed ID: 31839722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rivaroxaban and Apixaban Anti-Xa Measurements: Impact of Plasma Storage for 7 Days at Room Temperature.
    Boissier E; Genebrier S; Lakhal K; Nedelec-Gac F; Trossaërt M; Ternisien C; Gouin-Thibault I
    Thromb Haemost; 2018 Aug; 118(8):1488-1490. PubMed ID: 29960274
    [No Abstract]   [Full Text] [Related]  

  • 13. Evaluation of global laboratory methods and establishing on-therapy ranges for monitoring apixaban and rivaroxaban: Experience at a single institution.
    Park SH; Seo YH; Park PW; Kim KH; Seo JY; Lee HT; Kwoun WJ; Ahn JY
    J Clin Lab Anal; 2019 Jun; 33(5):e22869. PubMed ID: 30860622
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intraoperative monitoring of danaparoid sodium anticoagulation during cardiovascular operations.
    Gitlin SD; Deeb GM; Yann C; Schmaier AH
    J Vasc Surg; 1998 Mar; 27(3):568-75. PubMed ID: 9546248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
    Studt JD; Alberio L; Angelillo-Scherrer A; Asmis LM; Fontana P; Korte W; Mendez A; Schmid P; Stricker H; Tsakiris DA; Wuillemin WA; Nagler M
    J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
    Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
    Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An assay to measure levels of factor Xa inhibitors in blood and plasma.
    Kim PY; Di Giuseppantonio LR; Wu C; Douketis JD; Gross PL
    J Thromb Haemost; 2019 Jul; 17(7):1153-1159. PubMed ID: 30985986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.
    Kreutz R; Persson PB; Kubitza D; Thelen K; Heitmeier S; Schwers S; Becka M; Hemmrich M
    J Thromb Haemost; 2017 Oct; 15(10):2017-2028. PubMed ID: 28805299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multianalyte Determination of NOACs Using LC-MS/MS and Comparison with Functional Coagulation Assays.
    Slavik L; Lukes J; Friedecky D; Zhanelova M; Nemcova M; Ulehlova J; Prochazkova J; Hlusi A; Palova M; Vaclavik J
    Clin Lab; 2018 Oct; 64(10):1611-1621. PubMed ID: 30336535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of apixaban anti-factor Xa assay and impact of body weight.
    Wasan SM; Feland N; Grant R; Aston CE
    Thromb Res; 2019 Oct; 182():51-55. PubMed ID: 31450008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.